Hypophosphatasia News and Research

RSS
Enobia announces positive results from ENB-0040 Phase II juvenile clinical trial for hypophosphatasia

Enobia announces positive results from ENB-0040 Phase II juvenile clinical trial for hypophosphatasia

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Enobia reports positive interim data from ENB-0040 enzyme replacement therapy study for children with HPP

Enobia reports positive interim data from ENB-0040 enzyme replacement therapy study for children with HPP

Enobia Pharma unveils findings from first HPP self-reported patient survey at ACMG 2010

Enobia Pharma unveils findings from first HPP self-reported patient survey at ACMG 2010

McGill, Enobia Pharma collaborate to develop treatments for serious genetic bone diseases

McGill, Enobia Pharma collaborate to develop treatments for serious genetic bone diseases

Enobia Pharma initiates study of bone-targeted enzyme replacement therapy for hypophosphatasia

Enobia Pharma initiates study of bone-targeted enzyme replacement therapy for hypophosphatasia

Enobia Pharma's clinical study of ENB-0040 for treating hypophosphatasia provides positive results

Enobia Pharma's clinical study of ENB-0040 for treating hypophosphatasia provides positive results

Potential hypophosphatasia therapy discovered

Potential hypophosphatasia therapy discovered